A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry

Background: Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. Objectives: The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2022-02, Vol.28 (2), p.237-246
Main Authors: Hillert, Jan, Tsai, Jon A, Nouhi, Mona, Glaser, Anna, Spelman, Tim
Format: Article
Language:English
Subjects:
Crotonates
Dimethyl Fumarate - therapeutic use
Humans
Hydroxybutyrates
Immunosuppressive Agents - therapeutic use
Medicin och hälsovetenskap
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Nitriles
Original Research Papers
Patients
Population studies
Quality of Life
Registries
Sweden
Toluidines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. Objectives: The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting. Methods: All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the analysis. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders. Results: A total of 353 teriflunomide patients were successfully matched to 353 DMF. There was no difference in the rate of overall treatment discontinuation by treatment group across the entire observation period (hazard ratio (HR) = 1.12; 95% confidence interval (CI) = 0.91–1.39; p = 0.277; reference = teriflunomide). Annualised relapse rate (ARR) was comparable (p = 0.237) between DMF (0.07; 95% CI = 0.05–0.10) and teriflunomide (0.09; 95% CI = 0.07–0.12). There was no difference in time to first on-treatment relapse (HR = 0.78; 95% CI = 0.50–1.21), disability progression (HR = 0.55; 95% CI = 0.27–1.12) or confirmed improvement (HR = 1.17; 95% CI = 0.57–2.36). Conclusion: This population-based real-world study reports similarities in treatment persistence, clinical effectiveness and quality of life outcomes between teriflunomide and dimethyl fumarate.
ISSN:1352-4585
1477-0970
1477-0970
DOI:10.1177/13524585211019649